Related Experiment Videos

Erectile dysfunction in heart failure patients

Ernst R Schwarz1, Saurabh Rastogi, Vishal Kapur

  • 1Division of Cardiology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA. ernst.schwarz@cshs.org

Journal of the American College of Cardiology
|September 19, 2006
PubMed

Insights

Chronic heart failure and erectile dysfunction often coexist due to shared risk factors and unique physiological impacts. Standard heart failure treatments can worsen sexual dysfunction, potentially leading to treatment noncompliance.

Area of Science:

  • Cardiology
  • Urology
  • Internal Medicine

Background:

  • Heart failure (HF) and erectile dysfunction (ED) are highly prevalent and frequently comorbid conditions.
  • Shared risk factors for HF and ED include diabetes mellitus, hypertension, smoking, and dyslipidemia.
  • Physiological changes in HF contribute to both organic and psychological factors causing ED.

Purpose of the Study:

  • To review the unique aspects of erectile dysfunction (ED) specifically within the heart failure (HF) patient population.
  • To highlight the interplay between HF pathophysiology, its treatment, and the development of ED.
  • To inform clinicians about the challenges in managing ED in HF patients.

Main Methods:

  • This is a review article.
  • Literature search on the comorbidity of heart failure and erectile dysfunction.
  • Analysis of shared risk factors and treatment implications.

Main Results:

  • HF and ED share common risk factors like diabetes, hypertension, smoking, and dyslipidemia.
  • HF itself presents unique organic and psychological factors contributing to ED.
  • Standard HF therapies (beta-blockers, digoxin, diuretics) can cause or exacerbate sexual dysfunction.

Conclusions:

  • Erectile dysfunction is a significant concern in patients with chronic heart failure.
  • Medication side effects from HF treatment can negatively impact sexual function and adherence.
  • Understanding these unique aspects is crucial for comprehensive patient care and management.

Related Concept Videos

Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...